GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Ghrelin regulates adipose tissue metabolism: Role in hepatic steatosis.
Rasineni. Karuna K; Kubik. Jacy L JL; Knight. Kurt L KL; Hall. Lukas L; Casey. Carol A CA; Kharbanda. Kusum K KK
Key Findings
- Alcohol‑induced rise in ghrelin reduces insulin secretion, leading to increased fat breakdown and more fatty acids delivered to the liver.
- Ghrelin directly impairs the formation of fat‑storing cells and cuts adiponectin release, a hormone that protects the liver.
- Ghrelin increases inflammatory cytokines (IL‑6, CCL2) from fat cells, further promoting liver inflammation.
- Using a ghrelin‑receptor antagonist in ethanol‑fed rats raised adiponectin levels and suggested a protective effect against liver fat.
Practical Outcomes
- If you use ghrelin‑stimulating peptides like GHRP‑6, you may increase the risk of fatty liver, especially if you drink alcohol or already have metabolic issues. Consider limiting or timing use, monitor liver enzymes and liver fat, and pair with strategies that boost insulin sensitivity or adiponectin (e.g., exercise, omega‑3s, metformin). In high‑risk individuals, a ghrelin‑blocking approach might be worth exploring under medical supervision.
Summary
The study shows that higher ghrelin levels – like those caused by alcohol or a ghrelin‑boosting peptide – can mess up fat metabolism, push more free fatty acids to the liver, lower the protective hormone adiponectin, and raise inflammatory signals, all of which promote fatty‑liver disease. Blocking ghrelin’s receptor helped reverse these effects in rats.
Abstract
Fatty liver is the earliest and most common response of the liver to consumption of excessive alcohol. Steatosis can predispose the fatty liver to develop progressive liver damage. Chief among the many mechanisms involved in development of hepatic steatosis is dysregulation of insulin-mediated adipose tissue metabolism. Particularly, it is the enhanced adipose lipolysis-derived free fatty acids and their delivery to the liver that ultimately results in hepatic steatosis. The adipose-liver axis is modulated by hormones, particularly insulin and adiponectin. In recent studies, we demonstrated that an alcohol-induced increase in serum ghrelin levels impairs insulin secretion from pancreatic β-cells. The consequent reduction in circulating insulin levels promotes adipose lipolysis and mobilization of fatty acids to the liver to ultimately contribute to hepatic steatosis. Because many tissues, including adipose tissue, express ghrelin receptor we hypothesized that ghrelin may directly affect energy metabolism in adipocytes. We have exciting new preliminary data which shows that treatment of premature 3T3-L1 adipocytes with ghrelin impairs adipocyte differentiation and inhibits lipid accumulation in the tissue designed to store energy in the form of fat. We further observed that ghrelin treatment of differentiated adipocytes significantly inhibited secretion of adiponectin, a hepatoprotective hormone that reduces lipid synthesis and promotes lipid oxidation. These results were corroborated by our observations of a significant increase in serum adiponectin levels in ethanol-fed rats treated with a ghrelin receptor antagonist verses the un-treated ethanol-fed rats. Interestingly, in adipocytes, ghrelin also increases secretion of interleukin-6 (IL-6) and CCL2 (chemokine [C-C motif] ligand 2), cytokines which promote hepatic inflammation and progression of liver disease. To summarize, the alcohol-induced increase in serum ghrelin levels dysregulates adipose-liver interaction and promotes hepatic steatosis by increasing the free fatty acid released from adipose for hepatic uptake, and by altering adiponectin and cytokine secretion. Taken together, our data indicates that targeting the activity of ghrelin may be a powerful treatment strategy.
Study Information
pubmed
2020
2020-03-11T00:00:00.000Z
10.1016/j.cbi.2020.109059
12
58